Jiaxing University Master Degree Cultivation Base, Zhejiang Chinese Medical University, Jiaxing, 314001, Zhejiang Province, China.
Department of Anesthesiology and Pain Research Center, The First Hospital of Jiaxing or The Affiliated Hospital of Jiaxing University, Jiaxing, 314001, Zhejiang Province, China.
Eur J Trauma Emerg Surg. 2024 Jun;50(3):1051-1061. doi: 10.1007/s00068-023-02418-2. Epub 2023 Dec 26.
Before tracheal intubation, it is essential to provide sufficient oxygen reserve for emergency patients with full stomachs. Recent studies have demonstrated that high-flow nasal oxygen (HFNO) effectively pre-oxygenates and prolongs apneic oxygenation during tracheal intubation. Despite its effectiveness, the use of HFNO remains controversial due to concerns regarding carbon dioxide clearance. The air leakage and unknown upper airway obstruction during HFNO therapy cause reduced oxygen flow above the vocal cords, possibly weaken the carbon dioxide clearance.
Patients requiring emergency surgery who had fasted < 8 h and not drunk < 2 h were randomly assigned to the high-flow group, who received 100% oxygen at 30-60 L/min through nasopharyngeal airway (NPA), or the mask group, who received 100% oxygen at 8 L/min. PaO and PaCO were measured immediately before pre-oxygenation (T0), anesthesia induction (T1), tracheal intubation (T2), and mechanical ventilation (T3). The gastric antrum's cross-sectional area (CSA) was measured using ultrasound technology at T0, T1, and T3. Details of complications, including hypoxemia, reflux, nasopharyngeal bleeding, postoperative pulmonary infection, postoperative nausea and vomiting (PONV), and postoperative nasopharyngeal pain, were recorded. The primary outcomes were PaCO measured at T1, T2, and T3. The secondary outcomes included PaO at T1, T2, and T3, CSA at T1 and T3, and complications happened during this trial.
Pre-oxygenation was administered by high-flow oxygen through NPA (n = 58) or facemask (n = 57) to 115 patients. The mean (SD) PaCO was 32.3 (6.7) mmHg in the high-flow group and 34.6 (5.2) mmHg in the mask group (P = 0.045) at T1, 45.0 (5.5) mmHg and 49.4 (4.6) mmHg (P < 0.001) at T2, and 47.9 (5.1) mmHg and 52.9 (4.6) mmHg (P < 0.001) at T3, respectively. The median ([IQR] [range]) PaO in the high-flow and mask groups was 404.5 (329.1-458.1 [159.8-552.9]) mmHg and 358.9 (274.0-413.3 [129.0-539.1]) mmHg (P = 0.007) at T1, 343.0 (251.6-428.7 [73.9-522.1]) mmHg and 258.3 (162.5-347.5 [56.0-481.0]) mmHg (P < 0.001) at T2, and 333.5 (229.9-411.4 [60.5-492.4]) mmHg and 149.8 (87.0-246.6 [51.2-447.5]) mmHg (P < 0.001) at T3, respectively. The CSA in the high-flow and mask groups was 371.9 (287.4-557.9 [129.0-991.2]) mm and 386.8 (292.0-537.3 [88.3-1651.7]) mm at T1 (P = 0.920) and 452.6 (343.7-618.4 [161.6-988.1]) mm and 385.6 (306.3-562.0 [105.5-922.9]) mm at T3 (P = 0.173), respectively. The number (proportion) of complications in the high-flow and mask groups is shown below: hypoxemia: 1 (1.7%) vs. 9 (15.8%, P = 0.019); reflux: 0 (0%) vs. 0 (0%); nasopharyngeal bleeding: 1 (1.7%) vs. 0 (0%, P = 1.000); pulmonary infection: 4 (6.9%) vs. 3 (5.3%, P = 1.000); PONV: 4 (6.9%) vs. 4 (7.0%, P = 1.000), and nasopharyngeal pain: 0 (0%) vs. 0 (0%).
Compared to facemasks, pre-oxygenation with high-flow oxygen through NPA offers improved carbon dioxide clearance and enhanced oxygenation prior to tracheal intubation in patients undergoing emergency surgery, while the risk of gastric inflation had not been ruled out.
This trial was registered prospectively at the Chinese Clinical Research Registry on 26/4/2022 (Registration number: ChiCTR2200059192).
对于饱胃的急诊患者,在进行气管插管前,提供充足的氧储备至关重要。最近的研究表明,高流量鼻氧(HFNO)在气管插管期间能有效地预充氧并延长无通气时的氧合。尽管 HFNO 有效,但由于担心二氧化碳清除率,其使用仍存在争议。HFNO 治疗过程中空气泄漏和上气道阻塞的未知性导致声带上方的氧气流量减少,可能会减弱二氧化碳清除率。
将禁食时间<8 小时且未饮酒时间<2 小时的需要紧急手术的患者随机分配至高流量组,通过鼻咽气道(NPA)接受 100%氧气,流速为 30-60 L/min;或面罩组,接受 100%氧气,流速为 8 L/min。分别在预充氧前(T0)、麻醉诱导时(T1)、气管插管时(T2)和机械通气时(T3)测量 PaO 和 PaCO。在 T0、T1 和 T3 时使用超声技术测量胃窦横截面积(CSA)。记录并发症的详细信息,包括低氧血症、反流、鼻咽出血、术后肺部感染、术后恶心呕吐(PONV)和术后鼻咽疼痛。主要结局是 T1、T2 和 T3 时测量的 PaCO。次要结局包括 T1、T2 和 T3 时的 PaO、T1 和 T3 时的 CSA 以及试验期间发生的并发症。
115 例患者通过 NPA(n=58)或面罩(n=57)给予高流量氧气预充氧。高流量组的平均(SD)PaCO 在 T1 时为 32.3(6.7)mmHg,面罩组为 34.6(5.2)mmHg(P=0.045),在 T2 时分别为 45.0(5.5)mmHg 和 49.4(4.6)mmHg(P<0.001),在 T3 时分别为 47.9(5.1)mmHg 和 52.9(4.6)mmHg(P<0.001)。高流量组和面罩组的中位数(IQR [范围])PaO 在 T1 时分别为 404.5(329.1-458.1 [159.8-552.9])mmHg 和 358.9(274.0-413.3 [129.0-539.1])mmHg(P=0.007),在 T2 时分别为 343.0(251.6-428.7 [73.9-522.1])mmHg 和 258.3(162.5-347.5 [56.0-481.0])mmHg(P<0.001),在 T3 时分别为 333.5(229.9-411.4 [60.5-492.4])mmHg 和 149.8(87.0-246.6 [51.2-447.5])mmHg(P<0.001)。高流量组和面罩组的 CSA 在 T1 时分别为 371.9(287.4-557.9 [129.0-991.2])mm 和 386.8(292.0-537.3 [88.3-1651.7])mm(P=0.920),在 T3 时分别为 452.6(343.7-618.4 [161.6-988.1])mm 和 385.6(306.3-562.0 [105.5-922.9])mm(P=0.173)。高流量组和面罩组的并发症数量(比例)如下:低氧血症:1(1.7%)例 vs. 9(15.8%)例(P=0.019);反流:0(0%)例 vs. 0(0%)例;鼻咽出血:1(1.7%)例 vs. 0(0%)例(P=1.000);肺部感染:4(6.9%)例 vs. 3(5.3%)例(P=1.000);PONV:4(6.9%)例 vs. 4(7.0%)例(P=1.000);和鼻咽疼痛:0(0%)例 vs. 0(0%)例。
与面罩相比,在接受紧急手术的患者中,通过 NPA 给予高流量氧气预充氧可改善二氧化碳清除率并增强气管插管前的氧合作用,同时尚未排除胃充气的风险。
本试验于 2022 年 4 月 26 日在中国临床试验注册中心进行了前瞻性注册(注册号:ChiCTR2200059192)。